FDA Comments on Recently Released Rare Disease Guidance for Industry
Jonathan Goldsmith, M.D., F.A.C.P., FDA’s Associate Director, Rare Diseases Program, Center for Drug Evaluation and Research, comments on the recently released draft guidance for industry on rare disease drug development. Given the complexity and challenges of developing and bringing to market new FDA-approved drugs to treat rare diseases, we're excited to see this topic garnering more support. Read more here: http://blogs.fda.gov/fdavoice/index.php/2015/09/another-tool-help
Biotech Primer's Drug Development Immersion
Patagonia will attend Biotech Primer's Drug Development Immersion course in West Windsor, NJ from February 11-12. Please reach out to us if you would like to connect. #drugdevelopment #biotech #fda #orphandrugs #patagonia
Dr. Jonathan K. Wilkin, MD, FAAD, joins Patagonia's Advisory Board
Patagonia Pharmaceuticals is delighted to announce that Dr. Jonathan K. Wilkin, MD, FAAD, has joined Patagonia's growing Advisory Board. Dr. Wilkin is the founding Director (retired) of the Division of Dermatology and Dental Products at the US Food and Drug Administration. Before going to the FDA, he was Director of Dermatology at the Ohio State University and Professor of Pharmacology and Medicine. He has over 130 publications in dermatology and clinical pharmacology.
D
